Clinical Trial Update: A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) [Phase 1]

View source ↗

Summary

Phase 1 study ASPEN-07 evaluating Evorpacept (ALX148) with Enfortumab Vedotin for urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Evorpacept (ALX148) (evorpacept)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 1 | Status: COMPLETED